Cigna Group (CI)
(Delayed Data from NYSE)
$358.58 USD
+9.74 (2.79%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $358.57 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$358.58 USD
+9.74 (2.79%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $358.57 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Centene Makes Investment in RxAdvance, Builds Partnership
by Zacks Equity Research
Centene's (CNC) transformative alliance with RxAdvance is another instance of Health insurers joining forces with pharmacy benefit managers to reduce the costs in the drug supply chain.
Cigna on Raters' Radar After Express Scripts Bid, Stock Down
by Zacks Equity Research
Cigna (CI) gets rating downgrade on a number of concerns related to the Express Scripts deal.
Buy These 3 Stocks as Healthcare Continues to Shift Gears
by Zacks Equity Research
Mergers and acquisition in the healthcare industry should aid long term-growth for companies.
Cigna to Take Over Express Scripts (ESRX) for $67 Billion
by Zacks Equity Research
Per a definitive agreement, Cigna will take over Express Scripts (ESRX) in a cash-and-stock transaction worth $67 billion.
Cigna, Express Script Deal to Continue Healthcare Reshuffle
by Zacks Equity Research
Cigna's (CI) acquisition of Express Scripts should transform it into a more diversified entity.
Hartford Financial to Buy Foremost Small Commercial Lines
by Zacks Equity Research
Hartford Financial's (HIG) acquisitions aim to improve its segmental performances.
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
Anthem Buys America's 1st Choice, Expands in Medicare Market
by Zacks Equity Research
Anthem's (ANTM) acquisition of America's 1st Choice falls in line with its strategy to expand in the Medicare Advantage market.
MetLife (MET) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Robust EMEA and Latin America segments aid MetLife (MET) in Q4. However, a dull performance at U.S., Asia and MetLife Holdings partially offsets this upside.
The Zacks Analyst Blog Highlights: Cigna, Burlington Stores and Anthem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cigna, Burlington Stores and Anthem
3 Stable Low-Beta Stocks to Buy During Volatile Markets
by Benjamin Rains
Markets began to rebound on Monday after their worst week in nearly two years. The Dow Jones Industrial Average and the S&P 500 both climbed over 1.30%. Still, analysts are divided over whether the recent sell-off is over just yet.
Cigna Q4 Earnings Top on Higher Enrollment, 2018 View Issued
by Zacks Equity Research
Cigna (CI) Q4 earnings grow on higher revenues, which gained from higher premium and fees and increase in membership.
Cigna (CI) Beats on Q4 Earnings & Revenues, Guides for 2018
by Zacks Equity Research
Cigna (CI) Q4 earnings gained on membership and revenue growth.
Will Higher Membership, Revenues Aid Cigna (CI) Q4 Earnings?
by Zacks Equity Research
Cigna's (CI) Q4 earnings should likely be aided by higher revenues from its healthcare, global supplement units, partly offset by Medicare membership loss.
Zacks Industry Outlook Highlights: Aetna, Humana, Cigna and Anthem
by Zacks Equity Research
Zacks Industry Outlook Highlights: Aetna, Humana, Cigna and Anthem
Zacks Industry Outlook Highlights: UnitedHealth, Humana, Cigna, Anthem and Centene
by Zacks Equity Research
Zacks Industry Outlook Highlights: UnitedHealth, Humana, Cigna, Anthem and Centene
Zacks Industry Outlook Highlights: Aetna, Cigna, UnitedHealth and CVS Health
by Zacks Equity Research
Zacks Industry Outlook Highlights: Aetna, Cigna, UnitedHealth and CVS Health
Will Catastrophe Loss Impact Travelers' (TRV) Q4 Earnings?
by Zacks Equity Research
Weak underwriting results and deteriorated combined ratio across segments might affect Travelers' (TRV) Q4 results.
3 Reasons Why Cigna (CI) is a Great Momentum Stock
by Zacks Equity Research
Cigna (CI )seems to be a great momentum stock on the back of favorable price performance both in short and long term.
Why the Earnings Streak Will Continue for Cigna (CI)
by Zacks Equity Research
Cigna (CI) has seen a nice short-term history of beating earnings estimates, and looks poised to crush analyst expectations in its next earnings report as well.
The Zacks Analyst Blog Highlights: Progressive, Cigna, Selective Insurance Group and Brighthouse Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Progressive, Cigna, Selective Insurance Group and Brighthouse Financial
Invest in These 4 Insurance Stocks Ahead of Q4 Earnings
by Zacks Equity Research
We choose four insurers with favorable characteristics to leverage investors' portfolio ahead of Q4 earnings.
Prudential (PRU) & Units' Ratings Retained by A.M. Best
by Zacks Equity Research
A.M. Best's rating action on Prudential (PRU) and its units reflects the company's solid operational efficiency, strong enterprise risk management, promising business profile and sturdy finances.
MTG or RDN: Which Stock is Stronger for Mortgage Insurance?
by Zacks Equity Research
On a comparative-analysis basis, we try and find out which stock, Radian Group (RDN) or MGIC Investment (MTG), is better positioned in terms of fundamentals.
Tenet Healthcare Grows on Acquisitions, Lower Revenues Hurt
by Zacks Equity Research
Tenet Healthcare (THC) gains from buyouts, divestitures and strategic initiatives. However, fall in revenues and high level of debt continue to bother.